200pct gains with this hot biotech [BKIT]

This is a paid advertisement provided to our customers. Although we have sent you this email, Schaeffer's Investment Research does not endorse this product nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised below.

The Company Behind The Single Biggest Breakthrough In Insomnia Since Ambien Is Now Public And Acting RIGHT Now Could Put A Fast 200% In Your Pocket Before March 1st... And Even Quadruple And Even QUINTUPLE Digit Gains Later! Blake Insomnia Therapeutics (BKIT) has just unveiled an insomnia solution that has almost ZERO side effects! This could spell the end for Ambien – and put BKIT in the driver's seat of their entire pharmaceutical niche! Greetings, The company you're going to learn about today could be more than that just the next big biotech stock to explode... They're a trailblazer in their industry and may have just discovered what could be the single biggest breakthrough for insomnia the world has ever seen. As we speak, the current king of the sleepless sector, Ambien, has been the go to pharmaceutical solution for the more than 60 Million Americans that suffer with this debilitating condition. The problem? Horrendous side effects like: Daytime Drowsiness Dry Mouth Stomach Pain Headaches Nausea Spasms Sleep Disorders Shaking Cognitive Disorders And More! Nightmares These effects distressed some patients so bad – they had to do without the one medication that helped them the most... But Blake Insomnia Therapeutics (BKIT) changes ALL of that! Their groundbreaking sleeplessness solution has virtually NONE of the negative side effects I just mentioned, and... They have patents in place to protect their formula!! This is HUGE! And could have just put little known BKIT at the very top of their industry. What A "Natural Monopoly" For BKIT Means For You Being the only pharmaceutical company in the world that has access to an insomnia fighting formulation with almost zero side effects could effectively create what's called a "naturally occurring monopoly"... Meaning that since BKIT owns all the rights to their therapy – it basically makes them the ONLY choice for people who want a good night's sleep while being able to function normally the next day. For the company this means success on an almost unprecedented level... But for shareholders (especially those lucky enough to get in early) this naturally occurring monopoly could mean HUGE profits! How big? Well, I've already mentioned how this stock could soar as much as 200% before the years out... But if everything goes the way it's capable of – early investors could be in store for gains of OVER 15,000%!! Yes... you heard that right, OVER 15,000%!!! I'll show you all the proof in my attached special report on Blake Insomnia Therapeutics (BKIT) – in it, I'll show you exactly why this company could be the only stock you need to keep in your portfolio for 2017. Select the button below to get all of the facts on BKIT. Best Regards, Eric Dickson Editor, Breakaway Stocks PS. Consider acting on BKIT now – before mainstream media gets a hold of this story. The moment we see the pundits and talking heads on CNN, MSNBC and FOX talking about Blake Insomnia Therapeutics – it'll be too late! Start your research on this groundbreaking company today!

This is a PAID ADVERTISEMENT provided to our customers. Although we have sent you this email, Schaeffer’s Investment Research does not endorse this product nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, If you wish to be excluded from future notices, do not reply to this message. Instead, please go to the following address:  http://ads.schaeffersresearch.com/schaeffers-unsubscribe-partner/?o=486781&e=IGNOBLE.EXPERIMENT@arconati.us DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Schaeffer’s Investment Research, Inc. "Schaeffer’s" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this advertisement. Schaeffer’s has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://www.sec.gov/consumer/cyberfr.htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.